R.E. Gomes Leite de Oliveira

Affiliatie VU Research Associate, Cancer Center Amsterdam Assistant Professor, Human genetics

Specialization

Focus of research

Key publications
Latest publications

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Embaby, A., Huijberts, S. C. F. A., Wang, L., Leite de Oliveira, R., Rosing, H., Nuijen, B., Sanders, J., Hofland, I., van Steenis, C., Kluin, R. J. C., Lieftink, C., Smith, C. G., Blank, C. U., van Thienen, J. V., Haanen, J. B. A. G., Steeghs, N., Opdam, F. L., Beijnen, J. H., Huitema, A. D. R., Bernards, R., & 2 othersSchellens, J. H. M. & Wilgenhof, S., 1 Aug 2024, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 30, 15, p. 3157-3166 10 p.
Research output: Contribution to journal › Article › Academic › peer-review
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
Wang, L., Jin, H., Jochems, F., Wang, S., Lieftink, C., Martinez, I. M., de Conti, G., Edwards, F., de Oliveira, R. L., Schepers, A., Zhou, Y., Zheng, J., Wu, W., Zheng, X., Yuan, S., Ling, J., Jastrzebski, K., Santos Dias, M. D., Song, J-Y., Celie, P. N. H., & 6 othersYagita, H., Yao, M., Zhou, W., Beijersbergen, R. L., Qin, W. & Bernards, R., Nov 2022, In: Nature Cancer. 3, 11, p. 1284-1299 16 p.
Research output: Contribution to journal › Article › Academic › peer-review
Genetic and compound screens uncover factors modulating cancer cell response to indisulam
Pogacar, Z., Groot, K., Jochems, F., Dos Santos Dias, M., Mulero-Sánchez, A., Morris, B., Roosen, M., Wardak, L., de Conti, G., Velds, A., Lieftink, C., Thijssen, B., Beijersbergen, R. L., Bernards, R. & Leite de Oliveira, R., 1 Sept 2022, In: Life Science Alliance. 5, 9, e202101348.
Research output: Contribution to journal › Article › Academic › peer-review
All publications

R.E. Gomes Leite de Oliveira

Specialization

Focus of research

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

Amsterdam UMC makes use of cookies